within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDiseaseGord.A02BC54_RabeprazoleCombinations;

model RabeprazoleCombinations
  extends Pharmacolibrary.Drugs.ATC.A.A02BC54;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A02BC54</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rabeprazole is a proton pump inhibitor (PPI) used to reduce gastric acid production. It is commonly indicated in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and conditions involving excessive gastric acid secretion. The 'combinations' formulation may include other agents for synergistic effect on gastric acid suppression. Rabeprazole is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>No published compartmental pharmacokinetic models specifically available for rabeprazole combination products (A02BC54); parameters herein are estimated based on known data for monotherapy in healthy adults.</p><h4>References</h4><ol><li><p>Roh, JS, et al., &amp; Jeon, TW (2024). 13-Week Repeated Oral Toxicity and Toxicokinetic Studies of Rabeprazole Sodium and Sodium Bicarbonate Combination in Dogs. <i>International journal of toxicology</i> 43(5) 472–490. DOI:<a href=\"https://doi.org/10.1177/10915818241261631\">10.1177/10915818241261631</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38897632/\">https://pubmed.ncbi.nlm.nih.gov/38897632</a></p></li><li><p>Sahoo, BK, et al., &amp; Pal, TK (2009). Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers. <i>Arzneimittel-Forschung</i> 59(9) 451–454. DOI:<a href=\"https://doi.org/10.1055/s-0031-1296424\">10.1055/s-0031-1296424</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19856792/\">https://pubmed.ncbi.nlm.nih.gov/19856792</a></p></li><li><p>Litalien, C, et al., &amp; Faure, C (2005). Pharmacokinetics of proton pump inhibitors in children. <i>Clinical pharmacokinetics</i> 44(5) 441–466. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00001\">10.2165/00003088-200544050-00001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871633/\">https://pubmed.ncbi.nlm.nih.gov/15871633</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end RabeprazoleCombinations;
